No Data
Improved Earnings Required Before Getein Biotech, Inc (SHSE:603387) Shares Find Their Feet
Getein Biotech, Inc (603387.SH): The company's Metis6000 fully automatic biochemical immune assembly line installed more than 20 units in the third quarter of 2024.
Gelonghui, November 12th | Getein Biotech, Inc. (603387.SH) stated at the performance online conference that the company's Metis6000 fully automatic biochemical immune pipeline had installed over 20 units in the third quarter of 2024, over 70 units in the first three quarters, and a total of over 120 units installed since going public. The units are mainly distributed in the inspection department, with a small number in the emergency department and endocrine department. Among them, the installation in tertiary hospitals accounts for over 30%, while in secondary hospitals, it accounts for over 40%. The terminals mainly cover testing items such as liver function, tumor markers, myocardium, infectious diseases, inflammation, sex hormones, glucose metabolism, gastric function, bone metabolism, and others.
Basal Egg Organism: Basal Egg Organism: Third Quarter Report 2024
Egg Biosciences: third quarter report 2024
Getein Biotech,Inc (603387.SH) released its performance for the first three quarters, with a net income of 0.202 billion yuan, a 11.69% year-on-year decrease.
Getein Biotech, Inc. (603387.SH) disclosed its third quarter report for 2024, achieving a revenue of 8....
Getein Biotech, Inc (603387.SH): The net income for the first three quarters was 0.202 billion yuan, a year-on-year decrease of 11.69%.
On October 30, Gleonhui announced its third-quarter report for 2024, with the company's revenue for the first three quarters of 0.88 billion yuan, a 12.10% year-on-year decrease; net income attributable to shareholders of listed companies was 0.202 billion yuan, a 11.69% year-on-year decrease; and basic earnings per share were 0.40 yuan.
Getein Biotech, Inc (SHSE:603387) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough